



Twelve-Month Volume Reduction Ratio Predicts Regrowth and Time to Regrowth in Thyroid Nodules Submitted to Laser Ablation: A 5-Year Follow-Up Retrospective Study

Jung Suk Sim, MD, PhD

Withsim Clinic, Seongnam, Korea

Keywords: *Thyroid; Ultrasound; Thermal ablation*

Dear Editor,

I read with great interest the report by Negro et al. (1) titled "Twelve-Month Volume Reduction Ratio Predicts Regrowth and Time to Regrowth in Thyroid Nodules Submitted to Laser Ablation: A 5-Year Follow-Up Retrospective Study." This study presented long-term follow-up results of single session laser ablation (LA) for symptomatic benign thyroid nodules. The authors suggested that: 1) approximately one-third of the laser-treated nodules exhibited technical failure at the 12-month follow-up and that the risk to regrowth correlated with the 12-month volume reduction ratio (VRR); 2) a 12-month VRR < 50.0% suggests the timely performance of a second session to prevent nodule regrowth. Their conclusions were

especially valuable for clinicians pursuing image-guided thyroid ablation (I-GTA) as an alternative to surgery (2).

Regarding the predictor for future regrowth after I-GTA, the authors suggested using the value of VRR at 12 months after LA. However, a previous study by Sim et al. (3) suggested initial ablation ratio (IAR) for the prediction of regrowth. We advised that an IAR < 70%, calculated one month after the radiofrequency ablation (RFA) predicts a VRR < 50% at 12-month follow-up (3). Thus, we can expect technical failure and initiate an additional treatment plan earlier by applying IAR. For example, five cases showed negative values of VRR at 12-month in Figure 3 (1). These nodules must have started to regrow before 12 months. If IAR were applied to those nodules, a re-treatment plan could have been initiated earlier leading to better results for the patients.

Regarding the measurement of nodule volume, the authors measured the entire nodule. A previous investigation of Sim et al. (4) introduced the concept of viable volume regrowth. We divided nodules after RFA into two parts—the ablated area and the viable area. By following-up the change of viable area volume, we suggested that regrowth could be noted before total nodule volume change is noted. Operators can predict regrowth as soon as possible by combining 12-month VRR and viable volume regrowth and accordingly plan a re-treatment option.

Lastly, I want to address the ultimate goal of the I-GTA. Although many authors consider VRR > 50% as therapeutic success (5, 6), regrowth from the incompletely ablated area is commonly reported three years after I-GTA (7, 8). Therefore the guideline from Korean Society of Thyroid Radiology suggested that the ultimate goal of I-GTA may be a more complete ablation of the benign thyroid nodule rather than VRR > 50% (2). We propose that long-term stable VRR should be the goal of I-GTA as an alternative to surgery (9). I hope the authors, as experts in this field, would share this opinion on the ultimate goal of the I-GTA.

In conclusion, the authors provided valuable data as a result of a 5-year follow-up after a single session LA and presented useful information to predict regrowth and the time to regrow through a 12-month VRR. Experts should conduct a thorough exchange of opinions to establish the ultimate goal of the I-GTA.

Received: May 16, 2020 **Revised:** May 16, 2020

Accepted: May 17, 2020

Corresponding author: Jung Suk Sim, MD, PhD, Withsim Clinic, 353 Hwangsaoul-ro, Bundang-gu, Seongnam 13590, Korea.

• E-mail: jungsuk.sim@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iD

Jung Suk Sim

<https://orcid.org/0000-0001-6803-3544>

REFERENCES

1. Negro R, Greco G, Deandrea M, Rucco M, Trimboli P. Twelve-month volume reduction ratio predicts regrowth and time to regrowth in thyroid nodules submitted to laser ablation: a 5-year follow-up retrospective study. *Korean J Radiol* 2020;21:764-772
2. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. *Korean J Radiol* 2018;19:632-655
3. Sim JS, Baek JH, Cho W. Initial ablation ratio: quantitative value predicting the therapeutic success of thyroid radiofrequency ablation. *Thyroid* 2018;28:1443-1449
4. Sim JS, Baek JH, Lee J, Cho W, Jung SI. Radiofrequency ablation of benign thyroid nodules: depicting early sign of regrowth by calculating vital volume. *Int J Hyperthermia* 2017;33:905-910
5. Papini E, Rago T, Gambelunghe G, Valcavi R, Bizzarri G, Vitti P, et al. Long-term efficacy of ultrasound-guided laser ablation for benign solid thyroid nodules. Results of a three-year multicenter prospective randomized trial. *J Clin Endocrinol Metab* 2014;99:3653-3659
6. Jung SL, Baek JH, Lee JH, Shong YK, Sung JY, Kim KS, et al. Efficacy and safety of radiofrequency ablation for benign thyroid nodules: a prospective multicenter study. *Korean J Radiol* 2018;19:167-174
7. Park HS, Baek JH, Park AW, Chung SR, Choi YJ, Lee JH. Thyroid radiofrequency ablation: updates on innovative devices and techniques. *Korean J Radiol* 2017;18:615-623
8. Lim HK, Lee JH, Ha EJ, Sung JY, Kim JK, Baek JH. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. *Eur Radiol* 2013;23:1044-1049
9. Sim JS, Baek JH. Long-term outcomes following thermal ablation of benign thyroid nodules as an alternative to surgery: the importance of controlling regrowth. *Endocrinol Metab (Seoul)* 2019;34:117-123